Grifols (GRFS) Depreciation & Amortization (CF) (2010 - 2020)
Grifols (GRFS) posted Depreciation & Amortization (CF) of $85.6 million for Q1 2020, down 65.48% quarter-over-quarter from $248.1 million in Q4 2019, and up 1.15% year-on-year from $84.7 million in Q2 2019.
Grifols (GRFS) Depreciation & Amortization (CF) (2010 - 2020) Analysis & Trends
Grifols (GRFS) has reported Depreciation & Amortization (CF) for 10 consecutive years, with $85.6 million the latest figure, recorded in Q1 2020.
- Depreciation & Amortization (CF) for Q1 2020 came in at $85.6 million, up 1.15% year-over-year; the trailing twelve-month figure through Dec 2021 was $85.6 million (down 74.34% YoY), and the FY2025 annual result was $523.8 million, up 11.92% from the prior year.
- Depreciation & Amortization (CF) was $85.6 million for Q1 2020 at Grifols, down from $248.1 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $248.1 million in Q4 2019 and troughed at $55.6 million in Q3 2016.
- Average Depreciation & Amortization (CF) over 5 years is $121.5 million, with a median of $85.1 million recorded in 2019.
- Year-over-year, Depreciation & Amortization (CF) soared 30.64% in 2019 and rose 1.15% in 2020.
- Over 5 years, Depreciation & Amortization (CF) stood at $55.6 million in 2016, then soared by 235.15% to $186.5 million in 2017, then increased by 1.84% to $189.9 million in 2018, then surged by 30.64% to $248.1 million in 2019, then slumped by 65.48% to $85.6 million in 2020.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $85.6 million in Q1 2020, $248.1 million in Q4 2019, and $84.7 million in Q1 2019.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dep. & Amort. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 509.00 Mn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 2.00 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 188.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 1.37 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 581.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 1.12 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 93.00 Mn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.61 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 85.64 Mn |
| Mar 31, 2020 | 85.64 Mn |
| Dec 31, 2019 | 248.08 Mn |
| Dec 31, 2019 | 248.08 Mn |
| Mar 31, 2019 | 84.66 Mn |
| Mar 31, 2019 | 84.66 Mn |
| Dec 31, 2018 | 189.89 Mn |
| Dec 31, 2018 | 189.89 Mn |
| Jun 30, 2018 | 65.73 Mn |
| Jun 30, 2018 | 65.73 Mn |
| Mar 31, 2018 | 64.97 Mn |
| Mar 31, 2018 | 64.97 Mn |
| Dec 31, 2017 | 186.46 Mn |
| Dec 31, 2017 | 186.46 Mn |
| Jun 30, 2017 | 58.53 Mn |
| Jun 30, 2017 | 58.53 Mn |
| Mar 31, 2017 | 56.80 Mn |
| Mar 31, 2017 | 56.80 Mn |
| Dec 31, 2016 | 55.19 Mn |
| Dec 31, 2016 | 55.19 Mn |